Double Imprinted Nanoparticles for Sequential Membrane-to-Nuclear Drug Delivery.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Efficient and site-specific drug delivery is crucial for cancer therapy.
• Conventional nanocarriers like antibody-drug conjugates are expensive and can cause severe side effects.
• Estrogen receptor alpha (ERα) is overexpressed in most breast cancers, making it a key therapeutic target.

Purpose of the Study:

• To develop novel, cost-effective molecularly imprinted nanoparticles (nanoMIPs) for targeted cancer drug delivery.
• To engineer nanoMIPs that specifically bind to ERα and deliver doxorubicin for enhanced breast cancer treatment.
• To demonstrate the efficacy of nanoMIPs in advanced 3D cancer models, bypassing the need for animal testing.

Main Methods:

• Utilized a double imprinting technique to create nanoMIPs targeting a linear epitope of ERα.
• Loaded nanoMIPs with the chemotherapeutic drug doxorubicin.
• Evaluated nanoMIPs' binding affinity to ERα and their cytotoxicity in ERα-overexpressing breast cancer cell lines and 3D cancer models.

Main Results:

• Developed nanoMIPs with cost-effectiveness and antibody-like affinity for ERα.
• Achieved receptor-mediated endocytosis and nuclear drug delivery upon specific binding to ERα.
• Demonstrated significantly enhanced cytotoxicity in ERα-positive breast cancer cells and validated efficacy in 3D cancer models.

Conclusions:

• NanoMIPs represent a promising, innovative drug delivery system for precision breast cancer treatment.
• The developed nanoMIPs overcome limitations of traditional nanocarriers, offering improved safety and affordability.
• This approach validates the clinical potential of nanoMIPs as novel therapeutic agents in oncology.